StockData

Inhibrx Biosciences vs Scinai Immunotherapeutics

INBX and SCNI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INBX and SCNI compare

Scinai Immunotherapeutics scores higher on the StockData Score (6 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINBXSCNI
Size and price
Market cap$1.1B–
Share price$74.18$0.372
Change, 1 year−6.3%−96.2%
Change, 5 years93.5%−100.0%
Beta (5Y)2.161.20
Employees11045
StockData Score
Total score16 (better)
Valuation score00
Growth score01 (better)
Performance score00
Health score15 (better)
Dividend score00
Valuation
FCF yield−12.2%–
Growth
Revenue growth (TTM)–99.2%
Revenue growth, 5Y average−36.8%–
Net income growth (TTM)–−273%
Profitability
Gross margin–−202%
Operating margin–−575%
Net margin–−634%
FCF margin–−462%
Return on equity–−84.8%
Return on invested capital–−74.7%
Financial health
Debt / equity–0.00
Interest coverage−5.9×–
Current ratio7.58 (better)1.56
Altman Z-score−1.02–
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions97.4%–
Held by insiders35.4%7.4%
Insider net buying, 12 months$6.1M–
Superinvestors holding1–
Short interest, % of float35.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.